Akèy › Sipwa › Pennsylvania › Philadelphia
Etid klinik pou Sipwa nan Philadelphia, PA
14 etid pou Sipwa ap chèche patisipan nan sit nan ak bò kote Philadelphia (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Ap rekriteFaz 3
- Clinical Renal Associates Ltd., Media · 12 mi lwen
- Suburban Research Associates, West Chester · 24 mi lwen
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Ap rekriteFaz 3
- Thomas Jefferson University - Medicine/GI and Hepatology, Philadelphia
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Ap rekriteFaz 3
- Thomas Jefferson University - Medicine/GI and Hepatology, Philadelphia
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Ap rekriteFaz 3
- Abington Medical Specialists, Horsham · 16 mi lwen
- Family Practice Associates, Wilmington · 25 mi lwen
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Ap rekriteFaz 3
- Keystone Clinical Studies, Plymouth Meeting · 12 mi lwen
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Ap rekriteFaz 3
- AURORA-1 Clinical Site, Philadelphia
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Ap rekriteFaz 3
- AURORA-2 Clinical Site, Philadelphia
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Ap rekriteFaz 3
- Suburban Research Associates - West Chester Office, West Chester · 24 mi lwen
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Ap rekriteFaz 3Volontè an sante akeyi
- ACCOMPLISH-2 Research Site, Philadelphia
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
Ap rekriteFaz 3
- UPA Ctr Weight and Eating Dis, Philadelphia
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Ap rekriteFaz 4
- Dermatology Associates of Plymouth Meeting, Plymouth Meeting · 12 mi lwen
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
Ap rekriteFaz 3
- Research Site, Philadelphia
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Ap rekriteFaz 3
- ACCOMPLISH-1 Research Site, Philadelphia
An Acceptance-Based Healthy Lifestyle Intervention for Diverse Adolescents
Ap rekriteVolontè an sante akeyi
- Drexel University, Philadelphia
Etid Sipwa nan lòt vil
- San Antonio, TX34 etid
- Houston, TX33 etid
- Chicago, IL28 etid
- Orlando, FL27 etid
- Las Vegas, NV23 etid
- Miami, FL23 etid
- Atlanta, GA20 etid
- Dallas, TX20 etid
- New York City, NY19 etid
- Jacksonville, FL19 etid
- Washington, DC19 etid
- Austin, TX18 etid
Lòt etid nan Philadelphia
- Kansè (tout kalite)59 etid
- Kansè nan tete56 etid
- Kansè Poumon ki pa ti selil51 etid
- Kansè Metastatik46 etid
- Kansè kolorektal44 etid
- Kansè ovè44 etid
- Kansè pwostat44 etid
- Kansè poumon36 etid
- Leksemi mieloïd egi34 etid
- Ensifizyans kadyak31 etid
- Kansè Endomèt28 etid
- Depresyon26 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.